Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Sustained release technology proves effective in vivo
January 2016
SHARING OPTIONS:

NEW YORK—A preclinical study of Ohr Pharmaceutical Inc.’s proprietary SKS sustained release technology has yielded positive results for the company. Using an animal model, it was found that sustained supratherapeutic levels of active drug could be reached in target ocular tissues, with a prolonged pharmacokinetic profile. Ohr's technology uses micro-fabrication techniques to create nano- and micro-particle drug formulations capable of providing sustained, predictable release of a therapeutic drug over a three- to six-month period. The company has four active pipeline programs underway in glaucoma, steroid-induced glaucoma, allergic conjunctivitis and protein delivery for retinal diseases.
 
“We are extremely pleased and encouraged by the performance of our sustained release platform technology in this in-vivo study. The versatility of this delivery technology makes it well suited to deliver hydrophilic or hydrophobic small molecules, as well as proteins with complex structures,” said Dr. Glenn Stoller, Ohr’s chief scientific officer.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.